



SINGAPORE O&G LTD.

(Company Registration Number 201100687M)

FOR IMMEDIATE RELEASE

Singapore O&G Ltd. achieved Growth of 21.1% in Group Revenue & 25.7% in Net Profit for FY 2015

- **FY 2015 Group revenue up 21.2% as compared to FY 2014**
- **FY 2015 net profit after tax up 25.7% as compared to FY 2014**
- **Net profit after tax margin remained steady at 32.5%**
- **Declared a final one-tier tax exempt dividend of 1.15 Singapore cents per share**

Singapore, 3 February 2016 – Singapore O&G Ltd. (“**SOG**” or collectively with its subsidiaries, the “**Group**”), a SGX Catalist listed company specialising in women’s healthcare, today announced its unaudited financial results for the financial year ended 31 December 2015 (“**FY 2015**”). The Group’s net profit after tax attributable to shareholders increased by S\$1.1 million or 25.7%, and revenue increased by S\$2.9 million or 21.2%, as compared to FY 2014.

Financial Highlights

| S\$ | FY 2015 | FY 2014 | Change |
|---|------------|------------|---------|
| Revenue | 16,412,739 | 13,546,906 | ↑ 21.2% |
| Net profit after tax | 5,341,325 | 4,248,050 | ↑ 25.7% |
| Earnings per share (cents)[^] | 2.45 | 1.95 | ↑ 25.6% |

[^] Earnings per share is calculated based on the net profit after tax for FY 2014 and FY 2015 and 218,000,000 shares of the Company for illustration purposes only.

The increase in revenue is due to the full-year contribution of S\$1.5 million from our new Cancer Specialists clinics (SOG-Cindy Pang Clinic for Women and SOG-Radhika Breast & General Surgicare), and an increase in patient loads of S\$1.4 million in our Obstetrics and Gynaecology (“**O&G**”) segment.

The Group notes that Cancer treatment uses more consumables and medical supplies. However, as revenue from Cancer treatment is still modest relative to O&G revenue, gross profit margin declined only marginally from 88.9% in FY 2014 to 88.7% in FY 2015.



SINGAPORE O&G LTD.

(Company Registration Number 201100687M)

Employee benefits expense increased by S\$1.5 million or 30.0% from S\$4.8 million for FY 2014 to S\$6.3 million for FY 2015 and this is mainly due to the full-year salary and benefits expense of the two Cancer Specialists, and the increase in clinical and management staff headcount to support the growth of the Group and the Company's listing in 2015.

Whilst most expense categories increased in tandem to the increase in revenue, the Group endeavours to contain its costs particularly for other operating expense category. Other operating expense increased slightly by 1.9% from S\$2.1 million for FY 2014 to S\$2.2 million for FY 2015. Overall, the Group achieved an increase in net profit after tax of S\$1.1 million or 25.7% from S\$4.2 million for FY 2014 to S\$5.3 million for FY 2015.

As at 31 December 2015, the Group's balance sheet remained healthy with net asset value of S\$24.0 million which comprised mainly cash and cash equivalents of S\$24.2 million. The Group generated a net operating cash flow of S\$6.4 million for FY 2015. There were no borrowings and no debt securities.

Pursuant to the Dividend Policy as set out in the Company's Offer Document dated 26 May 2015, the Group targets to distribute up to 90% of its net profit after tax to our shareholders for FY 2015. In view of our performance in FY 2015, the Board of Directors of SOG is pleased to declare a final one-tier dividend of 1.15 Singapore cents per share in respect of FY 2015 ("**Final Dividend**"). Together with an interim dividend of 0.88 Singapore cents per share that had been paid on 3 September 2015, this will constitute 87.2% of FY 2015 net profit after tax.



SINGAPORE O&G LTD.

(Company Registration Number 201100687M)

Dr. Ng Koon Keng, Group Chief Executive Officer said: “We are very pleased to be able to announce such a sterling set of results for our inaugural year after listing. On the back of our growth in Group’s revenue, the Group also increased its total number of deliveries from 1,462 babies in FY 2014 to 1,633 babies in FY 2015. This is an increase from 5.6% in 2014 to 6.7% in 2015 in the private delivery market. Our Women Cancer Specialists, Dr. Radhika and Dr. Cindy Pang also had a good first year, contributing S\$1.5 million or 9.5% to our Group’s revenue. We anticipate this segment of our revenue will continue to grow strongly and we are also happy to announce that we have recruited a new Breast Surgeon, Dr. Lim Siew Kuan, who will be joining us in May 2016. She will be a significant addition in our fight against cancer.

The Group is very excited that Dr. Joyce Lim is now part of SOG and we look forward to integrating her businesses and to scale her products and services across all our clinics. We remain very positive for the year ahead and we are delighted to be able to reward our shareholders with a full year dividend of 2.03 Singapore cents per share for FY 2015. We would also like to take this opportunity to wish everyone a Happy Lunar New Year”.

- END -



SINGAPORE O&G LTD.

(Company Registration Number 201100687M)

ABOUT SINGAPORE O&G LTD. (“SOG” or the “Group”)

SOG is a group of specialist medical practitioners in women’s healthcare with a long and established track record in the Obstetrics and Gynaecology (“O&G”) field. SOG’s particular focus is on pregnancy care and delivery, the female reproductive system, gynaecological and breast cancer, skin and aesthetic treatments, and other ancillary medical services.

The Group is led by Dr. Lee Keen Whye (Chairman), Dr. Ng Koon Keng (Group Chief Executive Officer) and its Executive Directors, Dr. Heng Tung Lan and Dr. Beh Suan Tiong. In particular, both Dr. Lee Keen Whye and Dr. Heng Tung Lan have more than 20 years’ experience in the O&G field. Additionally, Dr. Ng Koon Keng has business development, management, marketing and publishing experience and spearheads the marketing and business development activities of the Group.

For more information, please visit SOG’s website at www.sog.com.sg.

This press release has been prepared by the Company and its contents have been reviewed by the Company’s Sponsor, Hong Leong Finance Limited (the “Sponsor”), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (“SGX-ST”). The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr. Tang Yeng Yuen, Vice-President, Head of Corporate Finance. Telephone (65) 6415 9886.